scholarly journals Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group

2017 ◽  
Vol 92 (6) ◽  
pp. E105-E107 ◽  
Author(s):  
Anne-Sophie Michallet ◽  
Arnaud Campidelli ◽  
Helene Lequeu ◽  
Marie-Sarah Dilhuydy ◽  
Olivier Tournilhac ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Elderly Patients ◽  
Real World ◽  
Lymphocytic Leukemia ◽  
Very Elderly

scholarly journals Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort

Haematologica ◽  
2018 ◽  
Vol 104 (5) ◽  
pp. e208-e210 ◽  
Author(s):  
Maria Winqvist ◽  
Per-Ola Andersson ◽  
Anna Asklid ◽  
Karin Karlsson ◽  
Claes Karlsson ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Real World ◽  
Lymphocytic Leukemia ◽  
Compassionate Use

scholarly journals Real-world testing and treatment patterns in chronic lymphocytic leukemia: A SEER patterns of care analysis

Cancer ◽  
2018 ◽  
Vol 125 (1) ◽  
pp. 135-143 ◽  
Author(s):  
Erlene K. Seymour ◽  
Julie J. Ruterbusch ◽  
Jennifer L. Beebe-Dimmer ◽  
Charles A. Schiffer
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Real World ◽  
Treatment Patterns ◽  
Lymphocytic Leukemia ◽  
Patterns Of Care

scholarly journals Chronic Lymphocytic Leukemia in Elderly Patients: Own Experience

2017 ◽  
Vol 1 (17) ◽  
pp. 26-31
Author(s):  
O. Vyhovska ◽  
◽  
Ya. Vyhovska ◽  
O. Shalay ◽  
L. Lukavetskyy ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Elderly Patients ◽  
Lymphocytic Leukemia

Analyzing treatment patterns and time to the next treatment in chronic lymphocytic leukemia real-world data using automated temporal phenotyping.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e19512-e19512
Author(s):  
Kyeryoung Lee ◽  
Zongzhi Liu ◽  
Meng Ma ◽  
Yun Mai ◽  
Christopher Gilman ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Real World ◽  
Clinical Decision Making ◽  
Single Agent ◽  
Treatment Patterns ◽  
Lymphocytic Leukemia ◽  
Time Interval ◽  
Real World Data ◽  
World Data ◽  
Therapeutic Class

e19512 Background: Targeted therapy is an important treatment for chronic lymphocytic leukemia (CLL). However, optimal strategies for deploying small molecule inhibitors or antibody therapies in the real world are not well understood, largely due to a lack of outcomes data. We implemented a novel temporal phenotyping algorithm pipeline to derive lines of therapy (LOT) and disease progression in CLL patients. Here, the CLL treatment pattern and time to the next treatment (TTNT) were analyzed in real-world data (RWD) using patient electronic health records. Methods: We identified a CLL cohort with LOT from the Mount Sinai Data Warehouse (2003-2020). Each LOT consisted of either a single agent or combinations defined by NCCN CLL guidelines. We developed a natural language processing (NLP)-based temporal phenotyping approach to automatically identify the number of lines and therapeutic regimens. The sequence of treatment and time interval for each patient were derived from the systematic treatment data. Time to event analysis and multivariate (i.e., age, gender, race, other treatment patterns) Cox proportional hazard (CoxPH) models were used to analyze the patterns and predictors of TTNT. Results: Four hundred eleven CLL patients received 1 to 7 LOTs. Ibrutinib was the predominant 1st LOT (40.8% of patients) followed by anti-CD20-based antibody therapies and chemotherapy in 30.6 and 19.2% of patients, respectively, followed by Acalabrutinib, Venetoclax, and Idelalisib in 3.4, 2.7, and 0.7% of patients, respectively (Table 1). The 2nd to 5th LOT showed the same or similar trends. We next analyzed the TTNT in the 1st line of each therapeutic class. Acalabrutinib resulted in a longer median TTNT than Ibrutinib. Both Acalabrutinib and Ibrutinib showed longer TTNT compared to Venetoclax (median TTNTs were 742 and 598 vs. 373 days: HR = 0.23, p=0.015 and HR = 0.48, p=0.03, respectively). In addition, patients with age equal to or older than 65 showed longer TNNT (HR=0.16, p=0.016). Conclusions: Our result shows the potential of RWD usage in clinical decision making as real-world evidence reported here is consistent with results derived from clinical trial data. Linking this study to genetic data and other covariates affecting treatment outcomes may provide additional insights into the optimal sequences of the targeted therapies in CLL. Table 1: Therapeutic class and patient numbers (%) in each line.[Table: see text]

Sign in / Sign up

Export Citation Format

Share Document